Indefinite Delivery Contract 36E79725D0031

Award Date 7/1/25
Last Date to Order 6/30/26
Ultimate Awardee
Not listed
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The federal government has awarded Novo Nordisk Inc., a global healthcare company, an Indefinite Delivery Contract (IDC) worth up to $470,487,013.27 to supply various types of human insulin. The single-award IDC was issued by the Department of Veterans Affairs' (VA) National Acquisition Center and has a period of performance from July 1, 2020 to June 30, 2025, with a one-year base period and four one-year option periods. The IDC aims to ensure an uninterrupted, cost-effective supply of...
The Department of Veterans Affairs (VA) National Acquisition Center has awarded Organon LLC a single-award Indefinite Delivery Contract (IDC) valued at $325,063,436.44 to provide Adalimumab pen and syringe kits. The contract has a base year of March 9, 2024 to March 8, 2025, with four one-year option periods, for a total potential period of performance through March 8, 2026. The IDC will support the VA's Pharmaceutical Prime Vendor program, as well as provide Adalimumab products to the Bureau of...
The Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Indefinite Delivery Contract (IDC) to Embecta Corp, doing business as Berra Newco Inc., for the procurement of insulin syringes. The contract has a ceiling value of $23,217,097 and a period of performance from April 23, 2023 to April 22, 2024, with four one-year option periods. The IDC was awarded as an unrestricted procurement to provide a continuous supply of various insulin syringe configurations to...
This indefinite delivery contract (IDC) was awarded by the National Acquisition Center, a civilian agency within the Department of Veterans Affairs (VA), to Zydus Pharmaceuticals (USA) Inc. The contract is for the supply of Dipeptidyl-Peptidase 4 (DPP-4) Inhibitor pharmaceutical products, including specific drugs like alogliptin, linagliptin, saxagliptin, and sitagliptin. The estimated annual requirement is 45,519,048 tablets, to be distributed through the VA's Pharmaceutical Prime Vendor...
This indefinite delivery contract was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Novo Nordisk Inc., a global healthcare company specializing in diabetes care and other specialty pharmaceuticals. The contract has a ceiling value of $598,189,800 and a period of performance from November 2, 2020 through November 1, 2025, with four one-year option periods. The contract vehicle procures once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist drugs,...
The federal contract indefinite delivery vehicle (IDV) is a Federal Supply Schedule (FSS) contract awarded by the Department of Veterans Affairs (VA) to Novo Nordisk Inc., a global healthcare company specializing in diabetes care and solutions for rare bleeding disorders, growth hormone related disorders, and obesity. The contract, valued at up to $553,107,000, is part of the GSA's Pharmaceuticals and Drugs schedule (FSS-61-IB) and allows federal agencies to procure a variety of specialty...
The federal contract IDV award is a single-award Indefinite Delivery Contract (IDC) with a ceiling value of $4,999,999.00, awarded by the Defense Logistics Agency (DLA) to the prime contractor DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valid through December 2036, covers the procurement of a comprehensive range of pharmaceutical products and medical supplies to support the recurring medical needs of military healthcare facilities...
The federal contract IDV award is a Federal Supply Schedule (FSS) contract administered by the Department of Veterans Affairs Veterans Health Administration (VA VHA). The prime contractor, Mylan Specialty LP, was awarded a multiple award FSS contract under the Pharmaceuticals and Drugs (FSS-61-IB) schedule, with a ceiling value of $514,849,130 and a period of performance running through January 2027. The contract enables the VA to issue task orders to procure pharmaceuticals, drugs, hematology...
This indefinite delivery contract (IDC) was awarded by the National Acquisition Center, a civilian federal agency, to Avkare LLC, a pharmaceutical and medical supply company, to provide a wide range of pharmaceutical products to the Department of Veterans Affairs (VA), Department of Defense (DoD), Bureau of Prisons (BOP), and Indian Health Service (IHS). The contract has a total ceiling value of $12,991,472.85 and a period of performance from March 16, 2020 to March 15, 2025. It was awarded as a...
The Department of Veterans Affairs National Acquisition Center awarded a single-award Indefinite Delivery Contract to QYK Brands LLC to provide various pen needle products. The contract utilizes no set-asides and has a potential value of $24.8 million with a period of performance from December 2022 through December 2023 and four one-year option periods. The originating pre-solicitation notice sought pen needles in five package sizes and gauge configurations for distribution through the VA's...

This single-award Indefinite Delivery Contract (IDC) was awarded by the Department of Veterans Affairs (VA) National Acquisition Center to Sanofi-Aventis U.S. LLC to provide a range of human insulin products, including pens, vials, and analogs, to multiple federal agencies including the VA, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The $465,370,525.50 ceiling value contract has a one-year base period from July 1, 2025 to June 30, 2026, with four one-year option periods.

The contract will be distributed through the VA and DoD pharmaceutical prime vendor programs and encompasses three distinct insulin product groups: Group 1 (human insulin pens and vials), Group 2 (rapid-acting analog insulin), and Group 3 (long-acting insulin). The estimated annual usage across these product groups ranges from approximately 39,444 units for Human 70/30 pens to 1,875,294 units for long-acting pens, indicating a substantial contract value. The solicitation, which will be issued under NAICS code 325412 for Pharmaceutical Preparation Manufacturing, does not utilize any set-asides, and is open to all qualifying vendors.

Generated 5/9/25, 9:55 AM